{
    "root": "33736c84-74d6-6f0e-e063-6394a90a9cc4",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Phentermine Hydrochloride",
    "value": "20250423",
    "ingredients": [
        {
            "name": "CROSPOVIDONE (15 MPA.S AT 5%)",
            "code": "68401960MK"
        },
        {
            "name": "DIBASIC CALCIUM PHOSPHATE DIHYDRATE",
            "code": "O7TSZ97GEP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_77635"
        },
        {
            "name": "FD&C BLUE NO. 1",
            "code": "H3R47K3TBD"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "POVIDONE, UNSPECIFIED",
            "code": "FZ989GH94E"
        },
        {
            "name": "PHENTERMINE HYDROCHLORIDE",
            "code": "0K2I505OTV",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50506"
        }
    ],
    "indications": {
        "text": "phentermine hydrochloride indicated short-term ( weeks ) adjunct regimen weight reduction based exercise , behavioral modification caloric restriction management exogenous obesity patients initial body mass index \u2265 30 kg/m 2 , \u2265 27 kg/m 2in presence risk factors ( e.g . , controlled hypertension , diabetes , hyperlipidemia ) . chart body mass index ( bmi ) based various heights weights . bmi calculated taking patient 's weight , kilograms ( kg ) , divided patient 's height , meters ( ) , squared . metric conversions follows : pounds \u00f7 2.2 = kg ; inches \u00d7 0.0254 = meters . body mass index ( bmi ) , kg/m 2 limited usefulness agents class , including phentermine hydrochloride tablets , [ pharmacology ( 12.1 , 12.2 ) ] measured possible risk factors inherent described .",
        "doid_entities": [
            {
                "text": "obesity (DOID:9970)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_9970"
            },
            {
                "text": "hypertension (DOID:10763)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_10763"
            },
            {
                "text": "diabetes (DOID:9351)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_9351"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "individualized obtain adequate response lowest effective dose . ( 2.1 ) late evening avoided ( risk insomnia ) . ( 2.1 ) phentermine hydrochloride tablets taken without food . ( 2.1 ) limit 15 mg daily patients severe renal impairment ( egfr 15 29 ml/min/1.73 2 ) ( 2.2 )",
        "doid_entities": [],
        "orphanet_entities": [
            {
                "disease": "severe renal impairment",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_447788"
            }
        ]
    },
    "warningsAndPrecautions": "phentermine hydrochloride tablets usp 37.5 mg ( equivalent 30 mg phentermine base ) white blue specks , oval shaped , scored one side debossed mp 273 side . bottles 30 ndc 53489-676-07 bottles 60 ndc 53489-676-06 bottles 100 ndc 53489-676-01 bottles 250 ndc 53489-676-03 bottles 500 ndc 53489-676-05 bottles 1000 ndc 53489-676-10",
    "adverseReactions": "history cardiovascular disease ( e.g . , coronary artery disease , stroke , arrhythmias , congestive heart failure , uncontrolled hypertension ) within 14 days following monoamine oxidase inhibitors hyperthyroidism glaucoma agitated states history abuse pregnancy [ ( 8.1 ) ] nursing [ ( 8.3 ) ] known hypersensitivity , idiosyncrasy sympathomimetic amines",
    "indications_original": "Phentermine hydrochloride is indicated as a short-term (a few weeks) adjunct in a regimen of weight reduction based on exercise, behavioral modification and caloric restriction in the management of exogenous obesity for patients with an initial body mass index \u2265 30 kg/m\n \n  2, or \u2265 27 kg/m\n \n  2in the presence of other risk factors (e.g., controlled hypertension, diabetes, hyperlipidemia).\n\n \n                  Below is a chart of body mass index (BMI) based on various heights and weights.\n                  BMI is calculated by taking the patient's weight, in kilograms (kg), divided by the patient's height, in meters (m), squared. Metric conversions are as follows: \n    pounds \u00f7 2.2 = kg; inches \u00d7 0.0254 = meters.\n \n                  \n                     \n                     \n                        \n                           \n                              BODY MASS INDEX (BMI), kg/m\n     \n      2\n                              \n                           \n                        \n                        \n                           \n                              \n                           \n                        \n                     \n                  \n                  The limited usefulness of agents of this class, including phentermine hydrochloride tablets, [\n \n  see\n  \n   Clinical Pharmacology (12.1,\n  \n   12.2)\n                     ] should be measured against possible risk factors inherent in their use such as those described below.",
    "contraindications_original": "Dosage should be individualized to obtain an adequate response with the lowest effective dose. (2.1) Late evening administration should be avoided (risk of insomnia). (2.1) Phentermine hydrochloride tablets can be taken with or without food. (2.1) Limit the dosage to 15 mg daily for patients with severe renal impairment (eGFR 15 to 29 mL/min/1.73 m 2 ) (2.2)",
    "warningsAndPrecautions_original": "Phentermine hydrochloride tablets USP 37.5 mg (equivalent to 30 mg phentermine base) are white with blue specks, oval shaped, scored on one side and debossed MP 273 on the other side.\n                  \n                     \n                     \n                     \n                        \n                           \n                              Bottles of 30\n                           \n                           \n                              NDC 53489-676-07\n                           \n                        \n                        \n                           \n                              Bottles of 60\n                           \n                           \n                              NDC 53489-676-06\n                           \n                        \n                        \n                           \n                              Bottles of 100\n                           \n                           \n                              NDC 53489-676-01\n                           \n                        \n                        \n                           \n                              Bottles of 250\n                           \n                           \n                              NDC 53489-676-03\n                           \n                        \n                        \n                           \n                              Bottles of 500\n                           \n                           \n                              NDC 53489-676-05\n                           \n                        \n                        \n                           \n                              Bottles of 1000\n                           \n                           \n                              NDC 53489-676-10",
    "adverseReactions_original": "History of cardiovascular disease (e.g., coronary artery disease, stroke, arrhythmias, congestive heart failure, uncontrolled hypertension)\n                     During or within 14 days following the administration of monoamine oxidase inhibitors\n                     Hyperthyroidism\n                     Glaucoma\n                     Agitated states\n                     History of drug abuse\n                     Pregnancy [\n  \n   see\n   \n    Use in Specific Populations (8.1)\n                        ]\n \n  \n                     Nursing [\n  \n   see\n   \n    Use in Specific Populations (8.3)\n                        ]\n \n  \n                     Known hypersensitivity, or idiosyncrasy to the sympathomimetic amines",
    "drug": [
        {
            "name": "Phentermine Hydrochloride",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50506"
        }
    ]
}